SSY GROUP (02005.HK): Propylthiouracil Tablets and Calcium Gluconate and Sodium Chloride Injection Obtain Drug Registration Approvals, Deemed to Have Passed Consistency Evaluation
NewTimeSpace News: SSY GROUP (02005.HK) announced on 10 July that Propylthiouracil Tablets (50mg) and Calcium Gluconate and Sodium Chloride Injection have secured drug registration approvals issued by NMPA, both deemed to have passed consistency evaluation. Propylthiouracil Tablets are the third domestically approved product of this kind, indicated for hyperthyroidism. The injection is used for acute hypocalcaemia, magnesium poisoning and fluoride poisoning.
NewTimeSpace News: On 10 July 2026, SSY GROUP (02005.HK) released a voluntary announcement. The Group has obtained the drug production registration approval for Propylthiouracil Tablets (50mg). Classified as Category 4 chemical drug, the product is deemed to have passed consistency evaluation, making the Group the third domestic enterprise to receive approval. The medicine is mainly used for various types of hyperthyroidism in patients intolerant to methimazole.
Meanwhile, the Group obtained registration approval for Calcium Gluconate and Sodium Chloride Injection (50ml:1g/0.3375g). As a Category 3 chemical drug, it is also deemed to have passed consistency evaluation. It is indicated for the treatment of acute hypocalcaemia, magnesium poisoning and fluoride poisoning. Together with other approved specifications under the Group, it enriches the calcium preparation portfolio.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- SSY GROUP(02005.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 320.32 million, YoY increase of 12.99%
- SSY GROUP (02005.HK): Obtains production registration approval for sodium ozagrel injection, achieving full dosage form coverage
- SSY GROUP (02005.HK): Vitamin K1 Injection obtains NMPA drug production registration certificate, deemed to pass consistency evaluation
- SSY GROUP (02005.HK): Four Products Receive NMPA Drug Manufacturing Registration Approvals, Deepening Infusion Therapy and Ophthalmology Portfolio
- SSY Group (02005.HK): All 16 Specifications of 13 Pharmaceutical Varieties Proposed to Be Selected in the 12th National Centralized Drug Procurement
